The European Parliament has formally adopted new pharmaceutical legislation, including proposals for a new directive and a new regulation. 11 April 2024
The US Food and Drug Administration has given a green light to BrainStorm Cell Therapeutics (Nasdaq: BCLI) for the design of a Phase IIIb trial for NurOwn (MSC- 10 April 2024
Research suggests there will likely be strong uptake for the first USA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH). 9 April 2024
Nearly eight years after the UK voted to leave the European Union (EU), the government is still delaying on introducing certain new rules that impact the life s 9 April 2024
The US regulator has for once again rebuffed efforts on the part of Supernus Pharmaceuticals (Nasdaq: SUPN) to register its Parkinson’s disease candidate SPN-83 9 April 2024